Trial Profile
Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol greater than 25 pg/mL.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel poliglumex (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors CTI BioPharma
- 14 Oct 2020 Status changed from discontinued to withdrawn prior to enrolment.
- 14 Oct 2020 Status changed from discontinued to withdrawn prior to enrolment.
- 02 Oct 2020 Status changed from active, no longer recruiting to discontinued.